Aliko Scientific S A : Announces Award of Major Five-Year Public Tender at Federico II University Hospital

About this update from Ikonisys Sa

Financial Aliko Scientific Announces Award of Major Five-Year Public Tender at Federico II University Hospital 19/05/2026 Execution of the long-term strategy focused on recurring revenue and developing opportunities for sustainable growth About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: https://www.alikoscientific.com About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: https://www.ikonisys.com About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: https://www.hospitex.com CONTACTS Ikonisys Alessandro Mauri, CFO [email protected] NewCap Louis-Victor Delouvrier/Aurélie Manavarere, Investor Relations [email protected] Tel. +33 (0)1 44 71 94 94 NewCap Arthur Rouillé, Media Relations [email protected] Tel. +33 (0)1 44 71 00 15 Download the pdf Federico II University Hospital previous Aliko Scientific signs strategic memorandum of understanding with Cellay Inc. and secures first commercial customer in Arizona

View stock analysis, news, and events for Ikonisys Sa